RxDoctor Payments Data

Alex Nielson, MD

Internal Medicine · Longview, WANPI 1174012355

Payments from drug & device makers

$4,367in general payments, 2019–2025

Across 190 payments — averaging $22.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$676
  • Novartis$387
  • Amgen$337
  • Lilly USA, LLC$330
  • Novo Nordisk$207
  • Bayer$202
  • plus $2K from 42 others

What the payments were for

  • Food & beverage$4,11894%
  • Education$1995%
  • Other$501%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,367 in reported general payments places this provider in the 95th percentile of 2,038 internal medicine providers in Washington.

See all internal medicine providers in Washington

Medicare billing

Part B allowed, 2024
$79,577
Medicare patients
273
Services billed
2,541

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban24$23,393
FarxigaDapagliflozin Propanediol20$13,313
JardianceEmpagliflozin11$10,493
Albuterol Sulfate HfaAlbuterol Sulfate51$1,276
Rosuvastatin Calcium91$1,235
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen56$1,220
Gabapentin63$1,147
Fentanyl11$1,017
Levothyroxine Sodium83$935
Oxycodone Hcl51$760
Testosterone Cypionate19$740
Losartan Potassium68$657
Irbesartan48$613
Cefdinir27$573
Fluconazole24$506

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$99$23,39324 claims
AstraZenecaFarxiga$676$13,31320 claims
Boehringer IngelheimJardiance$29$10,49311 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$23$93583 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,038 internal medicine providers in Washington.

Other internal medicine in Longview

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →